Oppenheimer Asset Management Inc. Raises Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Oppenheimer Asset Management raised its stake in IDEXX by 13.0% to 34,100 shares, valued at about $23.07 million, while institutional investors collectively own roughly 87.84% of the stock.
• Company insiders have been net sellers — executives George Fennell and Michael Erickson sold large blocks and insiders disposed of 45,957 shares (~$29.86 million) over the past three months, leaving insiders with about 0.79% ownership.
• Analyst sentiment is mixed-to-positive with a consensus "Moderate Buy" and a $751 target; IDEXX beat Q4 EPS and revenue estimates and set FY2026 guidance of 14.29–14.80 EPS.

Oppenheimer Asset Management Inc. increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,100 shares of the company's stock after purchasing an additional 3,930 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in IDEXX Laboratories were worth $23,070,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in IDXX. Sigma Planning Corp increased its position in shares of IDEXX Laboratories by 8.7% in the fourth quarter. Sigma Planning Corp now owns 1,269 shares of the company's stock valued at $859,000 after acquiring an additional 102 shares during the period. Mogy Joel R Investment Counsel Inc. boosted its stake in shares of IDEXX Laboratories by 0.3% during the 4th quarter. Mogy Joel R Investment Counsel Inc. now owns 85,545 shares of the company's stock valued at $57,874,000 after purchasing an additional 272 shares in the last quarter. US Bancorp DE boosted its stake in shares of IDEXX Laboratories by 1.6% during the 4th quarter. US Bancorp DE now owns 15,502 shares of the company's stock valued at $10,488,000 after purchasing an additional 243 shares in the last quarter. Simplicity Wealth LLC boosted its stake in shares of IDEXX Laboratories by 16.0% during the 4th quarter. Simplicity Wealth LLC now owns 434 shares of the company's stock valued at $294,000 after purchasing an additional 60 shares in the last quarter. Finally, Chapin Davis Inc. boosted its stake in shares of IDEXX Laboratories by 3.2% during the 4th quarter. Chapin Davis Inc. now owns 8,191 shares of the company's stock valued at $5,541,000 after purchasing an additional 257 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

IDXX has been the topic of a number of research reports. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of IDEXX Laboratories in a research note on Monday. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating on the stock in a research note on Tuesday. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research note on Monday, February 9th. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 25th. Finally, Barclays dropped their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a research note on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $751.00.

Insider Activity

In other news, EVP George Fennell sold 11,345 shares of the business's stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares of the company's stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president directly owned 12,693 shares of the company's stock, valued at $7,963,334.34. The trade was a 29.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,957 shares of company stock valued at $29,862,109 over the last three months. Corporate insiders own 0.79% of the company's stock.

IDEXX Laboratories Stock Up 1.3%

Shares of IDEXX Laboratories stock opened at $560.80 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The company has a 50-day simple moving average of $589.55 and a two-hundred day simple moving average of $651.11. IDEXX Laboratories, Inc. has a 52-week low of $462.05 and a 52-week high of $769.98. The stock has a market capitalization of $44.54 billion, a PE ratio of 42.91, a price-to-earnings-growth ratio of 3.36 and a beta of 1.72.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.07 billion. During the same period in the previous year, the company earned $2.53 earnings per share. The firm's quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 14.54 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.